Cervomed Inc (CRVO) Stock Price, Quote & News

Company Profile

CervoMed Inc., a a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in DLB and certain other major neurologic...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 744 4400

Website: www.cervomed.com

Address:

20 Park Plaza, Suite 424, Boston, United States

Stu_padasso Mar. 19 at 3:54 PM

$CRVO markets are shite but this is going to be 2 and lower soon they really havent advanced anything

1 · Reply

Messerschmittbf109 Mar. 19 at 3:13 PM

$CRVO Clinical study 2b very good let's see if they will be on average smart and smart also for the shareholders who invested their money here

0 · Reply

Doom_Gloom_AR Mar. 19 at 2:33 PM

$CRVO FINAL CRVO POST I'm sorry friends I sold, this analysis went on and on the bottom line is, they will need a 2500-7000 person trial to show stat sig. in Ischemic stroke their p2 is not powered even remotely close to being able to achieve stat sig. They are unable to obtain funding for the LBD p3. I'm very disappointed but this isn't what I signed up for. I really thought boger would pull some strings. I guess their only option now is to hit up the scum biotech funds that will fund any company as long as they get triple warrant coverage. Should this company get the proper p3 funding I'll be back in size. Good luck out their bios r hard, till then I bid you adieu!

0 · Reply

Messerschmittbf109 Mar. 19 at 2:00 PM

$CRVO if this … start will start next 2-4 days

0 · Reply

BPler Mar. 19 at 11:44 AM

$CRVO At some point it becomes ridiculous to fully ignore the market value potential of Neflamapimod and hoping for dilution to snatch shares cheaper. It only needs one whale to correct the price to stay definitely above 20, even with new financing. CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology https://www.stocktitan.net/news/CRVO/cervo-med-announces-new-data-at-the-ad-pdtm-2026-scientific-h3ov9xpimp6u.html

0 · Reply

DARKP00L Mar. 19 at 11:43 AM

$CRVO 07:42 on Mar. 19 2026 Investigators To Present New Analyses From Phase 2b RewinD-LB Clinical Study Of Neflamapimod Being Developed By Cervomed #tradeideas

0 · Reply

DARKP00L Mar. 18 at 10:33 PM

$CRVO

0 · Reply

Messerschmittbf109 Mar. 18 at 10:27 PM

$CRVO next three days we will know how if the shit in this cafe is enough or the total incompetence of the board is at the end of the….

0 · Reply

Messerschmittbf109 Mar. 18 at 3:55 PM

$CRVO $CRDF Brothers in red …💩

0 · Reply

anachartanalyst Mar. 18 at 2:02 PM

$CRVO https://anachart.com/wp-content/uploads/ana_temp/1773842492_soc-img.jpg

0 · Reply

CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology

Mar 17, 2026, 7:30 AM EDT - 4 days ago

CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates

Mar 4, 2026, 7:30 AM EST - 17 days ago

CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies

Feb 17, 2026, 8:00 AM EST - 4 weeks ago

CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors

SCYX

Dec 4, 2025, 5:00 PM EST - 3 months ago

CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies

Dec 2, 2025, 7:00 AM EST - 3 months ago

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

Nov 24, 2025, 7:00 AM EST - 4 months ago

CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Oct 20, 2025, 8:00 AM EDT - 5 months ago

CervoMed to Present at the Emerging Growth Conference

Oct 8, 2025, 11:54 AM EDT - 5 months ago

CervoMed Drug Cut Dementia Progression Risk By 75% In Trial

Oct 8, 2025, 7:00 AM EDT - 5 months ago

CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies

Oct 2, 2025, 8:00 AM EDT - 6 months ago

CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference

Sep 17, 2025, 7:30 AM EDT - 6 months ago

CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference

Sep 3, 2025, 8:00 AM EDT - 7 months ago

CervoMed to Participate in Upcoming Investor Conferences

Jul 28, 2025, 11:20 AM EDT - 8 months ago

CervoMed's Dementia Data Show Slowed Disease Progression

Jul 28, 2025, 7:00 AM EDT - 8 months ago

CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration

Jul 8, 2025, 7:00 AM EDT - 9 months ago

CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025

May 12, 2025, 8:00 AM EDT - 11 months ago

CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Mar 25, 2025, 8:00 AM EDT - 1 year ago

CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)

Mar 10, 2025, 4:05 PM EDT - 1 year ago

CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

Jan 29, 2025, 8:00 AM EST - 1 year ago

CervoMed to Present at the 8th International Lewy Body Dementia Conference

Dec 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2024, 11:37 AM EST - 1 year ago

CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets

Dec 10, 2024, 10:10 AM EST - 1 year ago

CervoMed's stock craters 77% after failed trial of treatment for rare brain disease

Dec 10, 2024, 7:33 AM EST - 1 year ago

CervoMed's dementia drug fails to meet mid-stage trial goals

Dec 10, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies

Nov 27, 2024, 7:00 AM EST - 1 year ago

CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia

Nov 12, 2024, 7:00 AM EST - 1 year ago

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Nov 8, 2024, 9:55 AM EST - 1 year ago

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

Nov 4, 2024, 8:00 AM EST - 1 year ago

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Oct 29, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Oct 2, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference

Aug 22, 2024, 8:00 AM EDT - 1 year ago

CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies

Jul 30, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference

Jul 17, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Participate in the Emerging Growth Conference

Jul 11, 2024, 8:51 AM EDT - 1 year ago

CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024

Jun 11, 2024, 8:00 AM EDT - 1 year ago

CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies

May 20, 2024, 8:00 AM EDT - 1 year ago

CervoMed to Appoint William Elder as Chief Financial Officer

May 15, 2024, 8:00 AM EDT - 2 years ago

CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Apr 1, 2024, 8:00 AM EDT - 2 years ago

CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates

Mar 28, 2024, 8:30 AM EDT - 2 years ago

CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors

Mar 5, 2024, 8:00 AM EST - 2 years ago

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

Feb 21, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the BIO CEO and Investor Conference

Feb 12, 2024, 8:00 AM EST - 2 years ago

CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

Feb 7, 2024, 8:30 AM EST - 2 years ago

CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

Feb 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 67

Jan 5, 2024, 8:00 AM EST - 2 years ago

CervoMed to Participate in the Emerging Growth Conference 66

Nov 13, 2023, 7:00 AM EST - 2 years ago

CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights

Oct 25, 2023, 2:50 PM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies

Oct 24, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias

Oct 18, 2023, 7:00 AM EDT - 2 years ago

CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies

Stu_padasso Mar. 19 at 3:54 PM

$CRVO markets are shite but this is going to be 2 and lower soon they really havent advanced anything

1 · Reply

Messerschmittbf109 Mar. 19 at 3:13 PM

$CRVO Clinical study 2b very good let's see if they will be on average smart and smart also for the shareholders who invested their money here

0 · Reply

Doom_Gloom_AR Mar. 19 at 2:33 PM

0 · Reply

Messerschmittbf109 Mar. 19 at 2:00 PM

$CRVO if this … start will start next 2-4 days

0 · Reply

BPler Mar. 19 at 11:44 AM

0 · Reply

DARKP00L Mar. 19 at 11:43 AM

$CRVO 07:42 on Mar. 19 2026 Investigators To Present New Analyses From Phase 2b RewinD-LB Clinical Study Of Neflamapimod Being Developed By Cervomed #tradeideas

0 · Reply

DARKP00L Mar. 18 at 10:33 PM

$CRVO

0 · Reply

Messerschmittbf109 Mar. 18 at 10:27 PM

$CRVO next three days we will know how if the shit in this cafe is enough or the total incompetence of the board is at the end of the….

0 · Reply

Messerschmittbf109 Mar. 18 at 3:55 PM

$CRVO $CRDF Brothers in red …💩

0 · Reply

anachartanalyst Mar. 18 at 2:02 PM

$CRVO https://anachart.com/wp-content/uploads/ana_temp/1773842492_soc-img.jpg

0 · Reply

BPler Mar. 18 at 12:35 PM

$CRVO https://www.gurufocus.com/news/8718788/cervomed-crvo-planning-major-developments-in-2026

0 · Reply

DARKP00L Mar. 18 at 12:19 PM

$CRVO 08:19 on Mar. 18 2026 Chardan Capital Maintains Buy on CervoMed, Raises Price Target to $21 #tradeideas

1 · Reply

BPler Mar. 18 at 10:37 AM

$CRVO PT 15 to 21 upgraded https://www.marketscreener.com/news/chardan-raises-price-target-on-cervomed-to-21-from-15-keeps-buy-rating-ce7e5ed8d08ef321#:~:text=Chardan%20Raises%20Price%20Target%20on,MarketScreener

0 · Reply

Doom_Gloom_AR Mar. 18 at 2:55 AM

$CRVO Our house is bet on ischemic stroke, lets dig deeper. Stroke triggers ATP Depletion-> glutamate exitocxicity>Ca2 overload MASSIVE activation of stress kinases including p38 MAPK P38a is the central node of this second injury phase Cytokine production ↑ IL-1β ↑ TNF-α ↑ IL-6 Neflamapimod causes: ↓ IL-1β / TNF ↓ microglial overactivation ↓ endothelial activation Critical drug has to be given 6h to 7 days after a stroke maybe weeks tops Neflamapimod works in stroke if reducing p38α-driven secondary injury (inflammation + synaptic dysfunction) meaningfully preserves viable neurons and improves recovery. Review of stroke trials: Winners have restored blood flow Losers: Enlimomab - ICAM-1 Upreg Blcok leukocyte adhesion antibody was murine - triggered inflamtion made disease worse Natalizumab prevent cd/4 lymphoctye entry to brain, too downstream too late Il-1 anakira - mixed results single cytokine too narrow

1 · Reply

BPler Mar. 17 at 8:55 PM

$CRVO H.C. Wainwright reiterated a Buy rating and $25.00 price target on CervoMed (NASDAQ:CRVO) as the company prepares to present data on its drug candidate neflamapimod at a medical conference. https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-cervomed-stock-rating-on-conference-data-93CH-4565413

0 · Reply

Fraser100 Mar. 17 at 7:35 PM

$CRVO All of these great announcements in my opinion are more PR exercises than meaningful information. The big question is rarely addressed: What is the timeline? When will you complete Ph3? These companies just don’t seem to have the resources to move forward so they dodge this aspect and doing studies just takes on a life of its own. I like the Japanese approach where if the product is proven to be safe they do a provisional time limited approval (7 years I think) so that patients can access the drugs much earlier.

1 · Reply

Stu_padasso Mar. 17 at 4:06 PM

$CRVO was anyone able to listen today just looking for broad-strokes of what was said was unable to listen in

1 · Reply

BPler Mar. 17 at 12:23 PM

$CRVO I hope the stock price gets corrected up today, under 40M is incredible undervalued.

1 · Reply

LowCountryHooker Mar. 17 at 12:07 PM

$CRVO Today, we announced our fourth quarter and full year 2025 financial results and provided updates on the progress of our lead program, neflamapimod. During the year, we reported positive Phase 2b RewinD-LB clinical data at the Clinical Trials on Alzheimer’s Disease (CTAD) conference and obtained alignment with the FDA and global regulators on the design of our planned Phase 3 trial in dementia with Lewy bodies (DLB). Additional analyses from the trial will be presented at the AD/PD 2026 conference. We also look ahead to several potential milestones across the neflamapimod program in 2026, including the planned initiation of a Phase 3 trial in DLB, anticipated data from trials in ischemic stroke recovery and primary progressive aphasia, and the planned initiation of the EXPERTS-ALS trial. You can read more here: https://bit.ly/47A2DkG #DLB #Dementia #ALS #Biotech

0 · Reply

Doom_Gloom_AR Mar. 17 at 11:48 AM

$CRVO they betting da house on da ischemic strike read out. Damn broski. Confidence or Tom foolery?

0 · Reply

StocktwitsEarnings Mar. 17 at 11:30 AM

$CRVO Q4 '25 Earnings Results & Recap CervoMed plans to initiate a Phase 3 clinical trial for DLB in the second half of 2026, subject to available funding, following FDA alignment on key aspects of the trial.

0 · Reply

BPler Mar. 16 at 9:41 PM

$CRVO In today's analyst rating update, D. Boral Capital has maintained its "Buy" rating for CervoMed (CRVO), keeping the price target unchanged at $31.00 USD. https://www.gurufocus.com/news/8716146/cervomed-crvo-maintains-current-analyst-ratings-and-price-target-crvo-stock-news

0 · Reply

Market Cap	39.26M
Revenue (ttm)	4.01M
Net Income (ttm)	-26.97M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-672.57%
Debt to Equity Ratio	0.00

Volume	41,700
Avg Vol	96,994
Day's Range	N/A - N/A
Shares Out	9.26M
Stochastic %K	8%
Beta	-0.77
Analysts	Strong Sell
Price Target	$22.14